Literature DB >> 16730133

Re-excision of margins before breast radiation-diagnostic or therapeutic?

Derek B Chism1, Gary M Freedman, Tianyu Li, Penny R Anderson.   

Abstract

PURPOSE: To identify factors in breast cancer patients that predict the pathologic results of re-excision for close or positive margins and to determine the effect on local control. METHODS AND MATERIALS: We divided 1,044 patients with Stage I-II breast cancer with a close (< or =2 mm) or positive margin after initial excision into three groups. Group 1 included 199 patients without additional excision, Group 2 included 546 patients with re-excision found to be free of cancer, and Group 3 included 299 patients with re-excision and residual cancer. All patients were treated with radiotherapy with a median follow-up of 6.7 years.
RESULTS: The 10-year local control rate was 95% for Group 1 and 94% for Groups 2 and 3 (p = 0.788). Of the 846 patients, 65% had no residual disease on re-excision and 35% did have residual tumor. The factors significantly associated with positive re-excision findings were initial positive margins, positive nodes, Stage T2 tumor, and an extensive intraductal component. The 10-year local control rate was 95% for Group 2 vs. 91% for Group 3 (p = 0.038).
CONCLUSION: The low recurrence rates seen in this study suggest that selected patients with non-negative margins, particularly those with a low risk of having residual disease at re-excision, may be treated with radiotherapy.

Entities:  

Mesh:

Year:  2006        PMID: 16730133     DOI: 10.1016/j.ijrobp.2006.02.017

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  2 in total

1.  Margins! Margins. Margins? How Important Is Margin Status in Breast-Preserving Therapy?

Authors:  Jürgen Dunst; Kathrin Dellas
Journal:  Breast Care (Basel)       Date:  2011-10-31       Impact factor: 2.860

2.  Full-dose intra-operative radiotherapy with electrons (ELIOT) during breast-conserving surgery: experience with 1246 cases.

Authors:  U Veronesi; R Orecchia; A Luini; V Galimberti; G Gatti; M Intra; P Veronesi; M C Leonardi; M Ciocca; R Lazzari; P Caldarella; N Rotmensz; C Sangalli; L S Silva; D Sances
Journal:  Ecancermedicalscience       Date:  2008-02-26
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.